Raymond James Downgrades Verastem (VSTM) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
JMP Securities Downgrades Verastem (VSTM) to Market Perform
September 29, 2015 8:26 AM EDTJMP Securities downgraded Verastem (NASDAQ: VSTM) from Market Outperform to Market Perform.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $1.85 yesterday.
... MoreJefferies Downgrades Verastem (VSTM) to Hold
September 28, 2015 4:43 PM EDTJefferies downgraded Verastem (NASDAQ: VSTM) from Buy to Hold with a price target of $2.00 (from $18.00).
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreUBS Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:27 PM EDTUBS downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00.
For an analyst ratings summary and ratings history on Verastem click here. For more ratings news on Verastem click here.
Shares of Verastem closed at $5.67 yesterday.
... MoreMizuho Securities Downgrades Verastem (VSTM) to Neutral
September 28, 2015 1:25 PM EDTMizuho Securities downgraded Verastem (NASDAQ: VSTM) from Outperform to Neutral with a price target of $2.00 (from $21.00).
Analyst Eric Criscuolo commented, "We are downgrading VSTM from Buy to Neutral and lowering our PT from $21 to $2 following the failure of the COMMAND trial of... More
Roth Capital Downgrades Verastem (VSTM) to Neutral
September 28, 2015 9:37 AM EDTRoth Capital downgraded Verastem (NASDAQ: VSTM) from Buy to Neutral with a price target of $2.00 (from $23.00).
Analyst Joseph Pantginis commented, "There has been a major disappointment this morning as the pivotal COMMAND study using VS-6063 in mesothelioma was halted for futility following the... More
Verastem (VSTM) Ceases VS-6063 Phase 2 Enrollment in Mesothelioma Following DSMB Recommendation
September 28, 2015 7:01 AM EDTVerastem (NASDAQ: VSTM) announced that the Company has stopped enrollment in the Phase 2 registration-directed, double-blind, placebo-controlled study (COMMAND) of VS-6063 for patients with mesothelioma. The decision to stop enrollment for futility followed a Data Safety Monitoring Board (DSMB) review of a pre-planned interim analysis. The results of the analysis demonstrated that VS-6063 had a generally well... More
